Rasagiline improves freezing in a patient with primary progressive freezing gait.
Identifieur interne : 002405 ( PubMed/Corpus ); précédent : 002404; suivant : 002406Rasagiline improves freezing in a patient with primary progressive freezing gait.
Auteurs : Francisco Coria ; María Del Puig Cozar-SantiagoSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2008.
English descriptors
- KwdEn :
- Aged, 80 and over, Brain (drug effects), Brain (radionuclide imaging), Disease Progression, Gait Disorders, Neurologic (drug therapy), Gait Disorders, Neurologic (physiopathology), Gait Disorders, Neurologic (radionuclide imaging), Humans, Indans (therapeutic use), Male, Monoamine Oxidase Inhibitors (therapeutic use), Tomography, Emission-Computed, Single-Photon (methods).
- MESH :
- chemical , therapeutic use : Indans, Monoamine Oxidase Inhibitors.
- drug effects : Brain.
- drug therapy : Gait Disorders, Neurologic.
- methods : Tomography, Emission-Computed, Single-Photon.
- physiopathology : Gait Disorders, Neurologic.
- radionuclide imaging : Brain, Gait Disorders, Neurologic.
- Aged, 80 and over, Disease Progression, Humans, Male.
Abstract
We herein report the case of a 84-year-old man with a 4-year history of freezing of gait (FOG) consistent with the diagnosis of primary progressive freezing gait. Single photon emission tomography (SPECT) with a radiolabeled ligand of the dopamine transporter (DAT-SPECT) showed integrity of striatal dopaminergic terminals, whereas brain perfusion SPECT disclosed multiple areas of decreased perfusion in frontal and parietal lobes, as well as in the subcortical gray nuclei of both sides. Treatment with the new irreversible monoamine oxidase B inhibitor rasagiline at standard doses resulted in a rapid, dramatic, and sustained improvement of the frequency and duration of FOG episodes. In addition, brain perfusion SPECT after treatment showed a marked increase of the activity in all cortical areas as well as in the basal ganglia and thalamus. Rasagiline may prove to be an effective and safe treatment for this disabling condition.
DOI: 10.1002/mds.21868
PubMed: 18067186
Links to Exploration step
pubmed:18067186Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rasagiline improves freezing in a patient with primary progressive freezing gait.</title><author><name sortKey="Coria, Francisco" sort="Coria, Francisco" uniqKey="Coria F" first="Francisco" last="Coria">Francisco Coria</name><affiliation><nlm:affiliation>Clinic for Nervous System Disorders and Service of Neurology, Hospital Universitario Son Dureta, Palma de Mallorca, Spain. fcoriab@meditex.es</nlm:affiliation></affiliation></author><author><name sortKey="Cozar Santiago, Maria Del Puig" sort="Cozar Santiago, Maria Del Puig" uniqKey="Cozar Santiago M" first="María Del Puig" last="Cozar-Santiago">María Del Puig Cozar-Santiago</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1002/mds.21868</idno><idno type="RBID">pubmed:18067186</idno><idno type="pmid">18067186</idno><idno type="wicri:Area/PubMed/Corpus">002405</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rasagiline improves freezing in a patient with primary progressive freezing gait.</title><author><name sortKey="Coria, Francisco" sort="Coria, Francisco" uniqKey="Coria F" first="Francisco" last="Coria">Francisco Coria</name><affiliation><nlm:affiliation>Clinic for Nervous System Disorders and Service of Neurology, Hospital Universitario Son Dureta, Palma de Mallorca, Spain. fcoriab@meditex.es</nlm:affiliation></affiliation></author><author><name sortKey="Cozar Santiago, Maria Del Puig" sort="Cozar Santiago, Maria Del Puig" uniqKey="Cozar Santiago M" first="María Del Puig" last="Cozar-Santiago">María Del Puig Cozar-Santiago</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged, 80 and over</term><term>Brain (drug effects)</term><term>Brain (radionuclide imaging)</term><term>Disease Progression</term><term>Gait Disorders, Neurologic (drug therapy)</term><term>Gait Disorders, Neurologic (physiopathology)</term><term>Gait Disorders, Neurologic (radionuclide imaging)</term><term>Humans</term><term>Indans (therapeutic use)</term><term>Male</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Tomography, Emission-Computed, Single-Photon (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Indans</term><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Gait Disorders, Neurologic</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Gait Disorders, Neurologic</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Brain</term><term>Gait Disorders, Neurologic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged, 80 and over</term><term>Disease Progression</term><term>Humans</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We herein report the case of a 84-year-old man with a 4-year history of freezing of gait (FOG) consistent with the diagnosis of primary progressive freezing gait. Single photon emission tomography (SPECT) with a radiolabeled ligand of the dopamine transporter (DAT-SPECT) showed integrity of striatal dopaminergic terminals, whereas brain perfusion SPECT disclosed multiple areas of decreased perfusion in frontal and parietal lobes, as well as in the subcortical gray nuclei of both sides. Treatment with the new irreversible monoamine oxidase B inhibitor rasagiline at standard doses resulted in a rapid, dramatic, and sustained improvement of the frequency and duration of FOG episodes. In addition, brain perfusion SPECT after treatment showed a marked increase of the activity in all cortical areas as well as in the basal ganglia and thalamus. Rasagiline may prove to be an effective and safe treatment for this disabling condition.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">18067186</PMID><DateCreated><Year>2008</Year><Month>03</Month><Day>04</Day></DateCreated><DateCompleted><Year>2008</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Rasagiline improves freezing in a patient with primary progressive freezing gait.</ArticleTitle><Pagination><MedlinePgn>449-51</MedlinePgn></Pagination><Abstract><AbstractText>We herein report the case of a 84-year-old man with a 4-year history of freezing of gait (FOG) consistent with the diagnosis of primary progressive freezing gait. Single photon emission tomography (SPECT) with a radiolabeled ligand of the dopamine transporter (DAT-SPECT) showed integrity of striatal dopaminergic terminals, whereas brain perfusion SPECT disclosed multiple areas of decreased perfusion in frontal and parietal lobes, as well as in the subcortical gray nuclei of both sides. Treatment with the new irreversible monoamine oxidase B inhibitor rasagiline at standard doses resulted in a rapid, dramatic, and sustained improvement of the frequency and duration of FOG episodes. In addition, brain perfusion SPECT after treatment showed a marked increase of the activity in all cortical areas as well as in the basal ganglia and thalamus. Rasagiline may prove to be an effective and safe treatment for this disabling condition.</AbstractText><CopyrightInformation>2007 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coria</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinic for Nervous System Disorders and Service of Neurology, Hospital Universitario Son Dureta, Palma de Mallorca, Spain. fcoriab@meditex.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cozar-Santiago</LastName><ForeName>María del Puig</ForeName><Initials>Mdel P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>003N66TS6T</RegistryNumber><NameOfSubstance UI="C031967">rasagiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020233">Gait Disorders, Neurologic</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007189">Indans</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008996">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015899">Tomography, Emission-Computed, Single-Photon</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21868</ArticleId><ArticleId IdType="pubmed">18067186</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002405 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002405 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:18067186
|texte= Rasagiline improves freezing in a patient with primary progressive freezing gait.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:18067186" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |